Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Iron Protein Succinylate→

Iron Protein Succinylate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
Not available
Molecular formula
Not available
Molecular weight
Not available
Drug class
Oral iron replacement complexferric iron–protein succinylate
Mechanism of action
A ferric iron–protein succinylate complex designed to maintain iron solubility in the gastrointestinal tract and deliver iron for absorption. The protein component is digested in the small intestine, releasing iron for transferrin transport and haemoglobin synthesis.
Indications / reported uses
  • Oral treatment of iron deficiency and iron-deficiency anaemia with formulations authorised for ferric protein succinylate; elemental iron content and dosage are product-specific.

Sources: https://pubmed.ncbi.nlm.nih.gov/?term=iron+protein+succinylate+iron+deficiency · https://pubchem.ncbi.nlm.nih.gov/#query=iron%20protein%20succinylate · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Oral iron replacement complex; ferric iron–protein succinylate

Mechanism of action

A ferric iron–protein succinylate complex designed to maintain iron solubility in the gastrointestinal tract and deliver iron for absorption. The protein component is digested in the small intestine, releasing iron for transferrin transport and haemoglobin synthesis.

General use cases

  • Oral treatment of iron deficiency and iron-deficiency anaemia with formulations authorised for ferric protein succinylate; elemental iron content and dosage are product-specific.
Active moiety: ferric iron–protein succinylate complex (Related chemical form or complex; use the note below to understand the identity distinction.)

A ferric iron–protein complex; this should not be reduced to a simple iron salt without respecting the complex formulation.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Iron Protein Succinylate Environmental Risk Assessment (ERA) (the Iron Protein Succinylate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.